Antibodies targeting tumour necrosis factor have substantially advanced the treatment of paediatric inflammatory bowel disease. Understanding pharmacokinetics and therapeutic drug monitoring has led to increased efficacy and durability of response. Primary non-response is more common in ulcerative colitis than in Crohn’s disease, highlighting the need for alternative biologic agents and oral small molecules.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Turner, D. et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160, 1570–1583 (2021).
Kugathasan, S. et al. Prediction of complicated disease course for children newly diagnosed with Crohn’s disease: a multicentre inception cohort study. Lancet 389, 1710–1718 (2017).
Dhaliwal, J. et al. Phenotypic variation in paediatric inflammatory bowel disease by age: a multicentre prospective inception cohort study of the Canadian Children IBD Network. J. Crohns Colitis 14, 445–454 (2020).
Rinawi, F. et al. Long-term outcomes with adalimumab therapy in pediatric Crohn disease: associations with adalimumab exposure. J. Pediatr. Gastroenterol. Nutr. 74, 389–395 (2022).
Assa, A. et al. Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn’s disease compared with reactive monitoring. Gastroenterology 157, 985–996.e2 (2019).
Mack, D. R. et al. Canadian Association of Gastroenterology Clinical Practice Guideline for the medical management of pediatric luminal Crohn’s disease. Gastroenterology 157, 320–348 (2019).
Dubinsky, M. C. et al. Dashboard-driven accelerated infliximab induction dosing increases infliximab durability and reduces immunogenicity. Inflamm. Bowel Dis. 28, 1375–1385 (2022).
Ungaro, R. C. et al. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn’s disease. Aliment. Pharmacol. Ther. 51, 831–842 (2020).
Hyams, J. S. et al. Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study. Lancet 393, 1708–1720 (2019).
Church, P. C. et al. Intensified infliximab induction is associated with improved response and decreased colectomy in steroid-refractory paediatric ulcerative colitis. J. Crohns Colitis 13, 982–989 (2019).
A.M.G. has been a consultant for Abbvie, Amgen, Bristol Myers Squibb, Janssen, Lilly, Merck, Pfizer and has received speaker fees from Abbvie and Janssen. L.S. declares no competing interests.
About this article
Cite this article
Scarallo, L., Griffiths, A.M. Medical therapy of paediatric inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 19, 685–686 (2022). https://doi.org/10.1038/s41575-022-00686-8